$257 Million is the total value of GREAT POINT PARTNERS LLC's 34 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 233.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ADMS | Buy | ADAMAS PHARMACEUTICALS INC | $20,258,000 | +90.3% | 772,600 | +26.9% | 7.90% | +68.6% |
| VNDA | Buy | VANDA PHARMACEUTICALS INC | $17,939,000 | +38.9% | 1,413,599 | +1.8% | 6.99% | +23.0% |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $16,856,000 | – | 678,595 | +100.0% | 6.57% | – |
| SGYPQ | New | SYNERGY PHARMACEUTICALS DEL | $16,683,000 | – | 2,009,984 | +100.0% | 6.50% | – |
| DYAX | Buy | DYAX CORP | $12,528,000 | +216.9% | 472,739 | +100.4% | 4.88% | +180.7% |
| PRTK | New | PARATEK PHARMACEUTICALS INC | $10,703,000 | – | 415,338 | +100.0% | 4.17% | – |
| RLYP | New | RELYPSA INC | $7,942,000 | – | 240,000 | +100.0% | 3.10% | – |
| ADHD | Buy | ALCOBRA LTD | $7,777,000 | +40.4% | 1,189,086 | +20.9% | 3.03% | +24.4% |
| SNSS | Buy | SUNESIS PHARMACEUTICALS INC | $7,650,000 | +200.6% | 2,541,459 | +144.7% | 2.98% | +166.2% |
| BVX | Buy | BOVIE MEDICAL CORP | $7,477,000 | +551.9% | 2,680,000 | +458.3% | 2.92% | +477.2% |
| ATRS | New | ANTARES PHARMA INC | $5,824,000 | – | 2,800,000 | +100.0% | 2.27% | – |
| CLBS | New | CALADRIUS BIOSCIENCES INC | $4,630,000 | – | 2,476,120 | +100.0% | 1.80% | – |
| ZGNX | New | ZOGENIX INC | $4,200,000 | – | 2,500,000 | +100.0% | 1.64% | – |
| BIOD | New | BIODEL INC | $4,132,000 | – | 4,011,511 | +100.0% | 1.61% | – |
| SGNT | New | SAGENT PHARMACEUTICALS INC | $3,450,000 | – | 141,900 | +100.0% | 1.34% | – |
| XNPT | New | XENOPORT INC | $2,973,000 | – | 485,000 | +100.0% | 1.16% | – |
| EXEL | New | EXELIXIS INCput | $2,801,000 | – | 745,000 | +100.0% | 1.09% | – |
| OREX | New | OREXIGEN THERAPEUTICS INC | $2,178,000 | – | 440,000 | +100.0% | 0.85% | – |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $687,000 | – | 8,400 | +100.0% | 0.27% | – |
| BDSI | New | BIODELIVERY SCIENCES INTL IN | $82,000 | – | 10,300 | +100.0% | 0.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.